Inventiva S.A.
Inventiva S.A. (IVA): 5 pipeline candidates · 2 upcoming catalysts · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E -21.09 · 0% dilution
Lead: Approved
5 candidates
2 upcoming, next in ~469d
N/A
A transparent, data-derived signal for Inventiva S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$845.7M
Cash
$14.2M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| duloxetine | Approved |
| iva337 | Phase 3 |
| metformin | Approved |
| paliperidone | Approved |
| telmisartan | Approved |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$227.2M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 5,194,805 | $28.8M |
| caligan partners lp | 4,974,906 | $27.6M |
| millennium management llc | 2,987,613 | $16.6M |
| franklin resources inc | 2,461,565 | $13.7M |
| adar1 capital management, llc | 2,174,398 | $12.1M |
| polar capital holdings plc | 2,132,138 | $11.8M |
| andera partners | 1,818,181 | $10.1M |
| yu fan | 1,500,000 | $8.3M |
| boothbay fund management, llc | 1,470,407 | $8.2M |
| nea management company, llc | 1,462,586 | $8.0M |
Showing top 10 of 62 institutional holders of Inventiva S.A.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Inventiva S.A.'s pipeline?
Inventiva S.A. (IVA) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inventiva S.A.'s lead drug candidate?
Inventiva S.A.'s most advanced tracked candidate is duloxetine (Approved) for 1 INDICATIONS AND USAGE Duloxetine is indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatric patients 13 years of age and older Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules USP is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults and pediatric patients 13 years of age and older ( 1 ) Chronic musculoskeletal pain in adults ( 1 ).
What is Inventiva S.A.'s next catalyst?
Inventiva S.A.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and S" — expected September 30, 2027.
What is Inventiva S.A.'s market capitalization?
Inventiva S.A.'s market capitalization is approximately $845.7M.
Who is the CEO of Inventiva S.A.?
Mr. Andrew Obenshain is the chief executive officer of Inventiva S.A. (IVA).
Get the full picture on Inventiva S.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.